Details

Autor(en) / Beteiligte

• Younes, Ramy
• Govaere, Olivier
• Petta, Salvatore
• Miele, Luca
• Tiniakos, Dina
• Burt, Alastair
• David, Ezio
• Vecchio, Fabio M
• Maggioni, Marco
• Cabibi, Daniela
• Fracanzani, Anna L
• Rosso, Chiara
• Blanco, Maria J Garcia
• Armandi, Angelo
• Caviglia, Gian Paolo
• Zaki, Marco Y W
• Liguori, Antonio
• Francione, Paolo
• Pennisi, Grazia
• Grieco, Antonio
• Valenti, Luca
• Anstee, Quentin M
• Bugianesi, Elisabetta

Titel

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

Ist Teil von

• The American journal of gastroenterology, 2020-08, Vol.115 (8), p.1289-1292

Ort / Verlag

United States: Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins

Erscheinungsjahr

2020

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.